Format

Send to

Choose Destination
Sci Transl Med. 2017 May 24;9(391). pii: eaal2439. doi: 10.1126/scitranslmed.aal2439.

Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin".

Author information

1
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr.112, 70376 Stuttgart, Germany.
2
German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.
3
Department of Urology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany.
4
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Auerbachstr.112, 70376 Stuttgart, Germany. matthias.schwab@ikp-stuttgart.de.
5
Department of Clinical Pharmacology, University Hospital Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany.
6
Department of Pharmacy and Biochemistry, University of Tuebingen, 72076 Tuebingen, Germany.
PMID:
28539468
DOI:
10.1126/scitranslmed.aal2439
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center